Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SFRP5 Antibodies:
anti-Rat (Rattus) SFRP5 Antibodies:
anti-Mouse (Murine) SFRP5 Antibodies:
Go to our pre-filtered search.
note an increase in BMP ligand expression in Sfrp1a/5 depleted embryos, a phenotype similar to that seen in embryos with inhibited BMP signaling
Sfrp5 inhibits both canonical and non-canonical Wnt (show WNT2 Antibodies) signaling during embryonic and endodermal development
propose that XsFRP5 exerts an early regulatory function in the specification of the ventral pancreas, as well as a late function in controlling stomach size via inhibition of Wnt (show WNT2 Antibodies) signalling
The inverse association of serum Sfrp5 with beta-cell function suggests a detrimental role of Sfrp5 for insulin (show INS Antibodies) secretion also in humans. The severity of NAFLD (show TSC2 Antibodies) does not appear to affect this relationship. The weak association between serum Sfrp5 and insulin (show INS Antibodies) sensitivity was partially explained by body mass.
Results identify several coding and non-coding variants in the sFRP5 gene region, the majority of which resulted in a non-synonymous amino acid change in the protein. One of the variants (c.-3G[A) shows a trend towards association between the variant frequency and the obese phenotype.
Results indicate that miR (show MLXIP Antibodies)-125b can regulate SFRP5 expression and thus influence the growth and activation of cardiac fibroblasts.
Decreased first trimester serum Sfrp-5 levels are significantly associated with the increased risk of gestational diabetes mellitus.
Report reduced hepatic SFRP5 expression in morbidly women with NAFLD (show TSC2 Antibodies).
Data suggest that serum SFRP5 levels are up-regulated in subjects with newly diagnosed type 2 diabetes as compared to prediabetic or control subjects; subjects were matched for obesity/overweight/body mass index.
Serum WISP2 (show WISP2 Antibodies) correlated directly with fatty acid binding protein 4. Serum SFRP5 did not differ between obese (n=32) vs. nonobese (n=25) PCOS women, but reference women had lower SFRP5 (p<5x10(-6) as compared to both PCOS groups).
Sfrp5 represents a candidate for a mature adipocyte marker gene.
The wnt5a (show WNT5A Antibodies)/sFRP5 system is altered in human sepsis and might therefore be of interest for future studies on molecular pathophysiology of this common human disease.
Serum SFRP5 is regulated by weight status and seems to be correlated with metabolic disorders in children.
The balance of factors controlling fat deposition can be evaluated in part by the differential expression profiles of Mest (show MEST Antibodies) and Sfrp5 genes with functions linked to fat deposition as long as there is an active accumulation of fat mass.
the expression of Mest (show MEST Antibodies) and Sfrp5 were tightly associated across the 5 mouse strains with the highest and lowest expression occurring in DBA (show RPS19 Antibodies)/2J and C57BL/6J (B6) respectively suggesting a common mechanism for their regulation.
MicroRNA-124 regulates cell specification in the cochlea through modulation of Sfrp4 (show SFRP4 Antibodies) and Sfrp5.
although high sFRP5 expression inhibits B-lymphopoiesis in vivo, physiologically, it contributes to the preservation of very primitive lymphopoietic progenitors, including hematopoietic stem cells, under high estrogen levels
A role for SFRP5 in glucose metabolism and pancreatic beta-cell function indicates that the use of an anti-SFRP5 mAb as a potential approach to treat type 2 diabetes.
Sfrp5 mRNA expression and protein secretion depend on the differentiation of adipocytes. The dysregulation of Sfrp5 expression and secretion is directly correlated with insulin (show INS Antibodies) resistance.
We propose that Ift88 (show IFT88 Antibodies) and primary cilia regulate expression of Sfrp5 and Wnt (show WNT2 Antibodies) signaling pathways in growth plate via regulation of Ihh (show IHH Antibodies) signaling.
early progeny of Sox2 (show SOX2 Antibodies)-positive stem cells transiently expressed the Wnt (show WNT2 Antibodies) inhibitor Sfrp5
SFRP5 inhibits WNT (show WNT2 Antibodies) signaling to suppress oxidative metabolism and stimulate adipocyte growth during obesity.
data show Sfrp5 is an anti-inflammatory adipokine whose expression is perturbed in models of obesity and type 2 diabetes; in obesity, Sfrp5 secretion exerts salutary effects on metabolic dysfunction by controlling adipose tissue inflammatory cells
Secreted frizzled-related protein 5 (SFRP5) is a member of the SFRP family that contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzled proteins. SFRPs act as soluble modulators of Wnt signaling. SFRP5 and SFRP1 may be involved in determining the polarity of photoreceptor cells in the retina. SFRP5 is highly expressed in the retinal pigment epithelium, and moderately expressed in the pancreas.
, secreted frizzled-related sequence protein 5
, frizzled-related protein 1b
, secreted apoptosis related protein 3
, secreted apoptosis-related protein 3
, secreted frizzled-related protein 5